MHR 24

Drug Profile

MHR 24

Alternative Names: Human tumour necrosis factor; n-TNF-alpha

Latest Information Update: 30 Aug 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mochida Pharmaceutical
  • Developer Hayashibara; Mochida Pharmaceutical
  • Class Antineoplastics; Tumour necrosis factors
  • Mechanism of Action Tumour necrosis factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported CNS cancer; Lymphoma; Skin cancer; Urogenital cancer

Most Recent Events

  • 30 Aug 2001 No-Development-Reported for CNS cancer in Japan (Injection)
  • 30 Aug 2001 No-Development-Reported for Lymphoma in Japan (Injection)
  • 30 Aug 2001 No-Development-Reported for Skin cancer in Japan (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top